Clinical Trials
73 trialsNCT02750202 2026-01-23
TheraVACCS
University of Pretoria
Phase 3 Completed
NCT05087849 2025-10-02
Intralesional HPV Vaccine for Condylomata
University of California, San Francisco
Phase 1/2 Completed
NCT04635423 2025-08-11
V503-064
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT00092534 2025-08-01
FUTURE II
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT06915779 2025-04-08
Long Term Follow-up of HPV Vaccine in HIV (CTN 236)
University of British Columbia
Completed
NCT02377999 2025-02-24
Safety and Efficacy of Repeat Use of Picato® 0.05% in the Treatment of Anogenital Warts
LEO Pharma
Phase 2 Completed
NCT05100043 2025-02-19
Interleukin 4 and Interferon Gamma Predictors of Human Papillomavirus Immunotherapy in Warts
Zagazig University
Completed
NCT03981822 2024-11-27
CARE-1
Verrica Pharmaceuticals Inc.
Phase 2 Completed
NCT06700941 2024-11-22
Impact of HPV Vaccination Against Cervical Lesions and Genital Warts in Colombia. an Ecological Assessment
Universidad Nacional de Colombia
Completed
NCT06297187 2024-09-19
Cavitronic Ultrasonic Surgical Aspiration (CUSA) Women's Health Study
Integra LifeSciences Corporation
Completed
NCT05518201 2024-04-17
Evaluate the Safety and Immunogenicity of a 9-valent HPV Vaccine in Chinese Healthy Male Aged 9-45 Year-old
Shanghai Bovax Biotechnology Co., Ltd.
Phase 1 Completed
NCT06281353 2024-02-28
The Effect of Oral Nanocurcumin as an Adjuvant Therapy for Anogenital Warts: Evaluation of Clinical Improvement, NFĸB, IFN-γ, and FOXP3+TReg From Lesions Tissue
Indonesia University
Phase 2/3 Completed
NCT05372016 2023-11-24
Evaluate the Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females
Shanghai Bovax Biotechnology Co., Ltd.
Phase 3 Completed
NCT04782895 2023-06-15
Immunogenicity of a Recombinant Human Papillomavirus Nonavalent (Types 6,11,16,18,31,33,45,52,58)Vaccine(E.Coli) Versus Gardasil®9 in Healthy Females 18-26 Years of Age
Xiamen University
Phase 3 Completed
NCT03900572 2023-04-13
A Study of Safety and Primary Immunogenicity of 9-valent HPV Recombinant Vaccine
Shanghai Zerun Biotechnology Co.,Ltd
Phase 1 Completed
NCT02462187 2023-04-06
Topical NVN1000 for the Treatment of External Genital and Perianal Warts
Novan, Inc.
Phase 2 Completed
NCT00973856 2023-01-31
Evaluation of the Effectiveness of an Alcohol Based Hand Gel for the Reduction of Warts on the Hands
Cleveland Clinic Akron General
Phase NA Completed
NCT05694728 2023-01-23
A Phase II Trial Evaluate the Immunogenicity and Safety Profile of HPV Vaccine
Beijing Health Guard Biotechnology, Inc
Phase 2 Completed
NCT05680454 2023-01-17
A Phase I Trial Evaluate the Safety and Tolerability Profile of HPV Vaccine
Beijing Health Guard Biotechnology, Inc
Phase 1 Completed
NCT02405520 2022-05-24
Safety and Immunogenicity Study of the Recombinant Human Papillomavirus Virus Type 6/11 Bivalent Vaccine
Xiamen University
Phase 1 Completed
NCT04425291 2022-02-25
Evaluate the Immunogenicity and Safety of 4-valent and 9-valent HPV Recombinant Vaccine in Chinese Healthy Females
Shanghai Bovax Biotechnology Co., Ltd.
Phase 3 Completed
NCT00189293 2022-02-07
Study of Imiquimod Cream Prior to Ablative Therapy in External Ano-Genital Warts
Viatris Inc.
Phase 4 Completed
NCT05156541 2021-12-14
ING-HPV-1
SPP Pharmaclon Ltd.
Phase 3 Completed
NCT03813940 2021-04-08
Safety Study of Recombinant Human Papillomavirus Vaccine(6,11,16,18,31,33,45,52,58 Type)(E.Coli)
Xiamen University
Phase 1 Completed
NCT03935204 2021-04-08
Immunogenicity Study of Recombinant Human Papillomavirus Vaccine(6,11,16,18,31,33,45,52,58 Type)(E.Coli)
Xiamen University
Phase 2 Completed
NCT04796090 2021-03-15
Genital Wart and Sexuality in Adolescence
Ankara City Hospital Bilkent
Completed
NCT02482428 2021-01-05
Efficacy and Tolerability of Topical LFX453 for External Genital Warts
Novartis
Phase 2 Completed
NCT03546842 2020-02-25
V503-017
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT01796821 2020-02-05
Efficacy and Safety Profiles of SR-T100 Gel on External Genital Warts/Condyloma Acuminate(EGWs)
G&E Herbal Biotechnology Co., LTD
Phase 2 Completed
NCT03676101 2020-01-22
Evaluate the Safety and Primary Immunogenicity of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females
Shanghai Bovax Biotechnology Co., Ltd.
Phase 1 Completed
NCT03158220 2019-11-21
Immunogenicity and Tolerability of Broad Spectrum Human Papillomavirus (HPV) Vaccine in Adult and Young Adult Women (V503-004)
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT02188004 2019-05-07
The Epidemiologic Study of Human Papillomavirus Infection and Related Diseases
Xiamen University
Completed
NCT00543543 2018-11-27
Broad Spectrum HPV (Human Papillomavirus) Vaccine Study in 16-to 26-Year-Old Women (V503-001)
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT01047345 2018-11-27
A Study of V503, a 9-valent Human Papillomavirus (9vHPV) Vaccine in Females 12-26 Years of Age Who Have Previously Received GARDASILâ„¢ (V503-006)
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT01651949 2018-11-27
Multivalent HPV (Human Papillomavirus) Vaccine Study in 16- to 26-Year Old Men and Women (V503-003)
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT01245764 2018-11-14
GARDASILâ„¢ Study in Healthy Females Between 9 and 26 Years of Age in Sub-Saharan Africa (V501-046)
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT00090285 2018-08-23
V501-020
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT03625960 2018-08-10
Cantharone for the Treatment of Perenial Warts
Wayne State University
Phase 4 Completed
NCT02724254 2018-07-20
A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of Twice Daily Topical Applications of AP611074 5% Gel for up to 16 Weeks in Condyloma Patients
Vaxart
Phase 2 Completed
NCT02535104 2018-06-06
Safety and Efficacy Study of Topical Ranpirnase to Treat Genital Warts (HPV)
Tamir Biotechnology, Inc.
Phase 1/2 Completed
NCT01532102 2018-05-30
Safety and Efficacy Study of Topical AP611074 Gel to Treat Genital Warts
Vaxart
Phase 1/2 Completed
NCT02015260 2017-05-03
A Trial of the Efficacy and Safety of Topical Nitric Oxide in Patients With Anogenital Warts
University of Aberdeen
Phase 2 Completed
NCT02849262 2017-03-31
Pharmacodynamics, Safety and Efficacy of Topical Omiganan in Patients With External Genital Warts
Maruho Co., Ltd.
Phase 2 Completed
NCT00092482 2017-03-22
Immunogenicity Bridge Between an Investigational Monovalent Vaccine and the Equivalent Component of Gardasil (V501) a Quadrivalent Vaccine (V501-012)(COMPLETED)
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT00517309 2017-03-22
FUTURE
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT02558803 2016-05-25
HPV Vaccination: Evaluation of Reminder Prompts for Doses 2 & 3
Regenstrief Institute, Inc.
Phase NA Completed
NCT01520194 2016-05-10
GWburden
BEMFAM-Bem Estar Familiar
Completed
NCT02551887 2016-03-11
HPV Vaccination: An Investigation of Physician Reminders and Recommendation Scripts
Regenstrief Institute, Inc.
Phase NA Completed
NCT00851643 2016-02-03
Broad Spectrum HPV Vaccine Dose Escalation Study (V502-002)
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT01598779 2015-12-21
Human Papillomavirus (HPV) Types Present in External Genital Warts (EGW) in the Argentinean Population
University of Buenos Aires
Completed